Abstract
The new coronavirus disease 2019 (COVID-19) has required the implementation of severe mobility restrictions and social distancing measures worldwide. While these measures have been proven effective in abating the epidemic in several countries, it is important to estimate the effectiveness of testing and tracing strategies to avoid a potential second wave of the COVID-19 epidemic. We integrate highly detailed (anonymized, privacy-enhanced) mobility data from mobile devices, with census and demographic data to build a detailed agent-based model to describe the transmission dynamics of SARS-CoV-2 in the Boston metropolitan area. We find that enforcing strict social distancing followed by a policy based on a robust level of testing, contact-tracing and household quarantine, could keep the disease at a level that does not exceed the capacity of the health care system. Assuming the identification of 50% of the symptomatic infections, and the tracing of 40% of their contacts and households, which corresponds to about 9% of individuals quarantined, the ensuing reduction in transmission allows the reopening of economic activities while attaining a manageable impact on the health care system. Our results show that a response system based on enhanced testing and contact tracing can play a major role in relaxing social distancing interventions in the absence of herd immunity against SARS-CoV-2.
Competing Interest Statement
MEH reports grants from the National Institute of General Medical Sciences during the conduct of the study; AV reports grants and personal fees from Metabiota, Inc., outside of the submitted work; MC and APyP report grants from Metabiota, Inc., outside of the submitted work. The authors declare no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
NED, IML, MEH, APP and AV acknowledge the support of NIH/NIAID AI139761. MC and AV acknowledge support from Google Cloud Healthcare and Life Sciences Solutions via the GCP research credits program. MEH acknowledges support from the NIH/NIGMS U54 GM111274 EM acknowledges partial support by MINECO (FIS2016-78904-C3-3-P). YM acknowledges partial support from the Government of Aragon and FEDER funds, Spain through grant E36-17R (FENOL), and by MINECO and FEDER funds (FIS2017-87519-P). AA and YM acknowledge support from Intesa Sanpaolo Innovation Center. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Under request.
